Replies to post #341662 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

In 2022, which disappears, blarcamesine or Aduhelm?

Biogen couldn't even imagine Anavex as a possible solution or future deadly competitor. They were going down with their amyloid ship and are now looking for a tow.

For both Biogen with Aduhelem and Anavex with blarcamesine, 2022 will be the make or break year.

Personally, from what I know of the demonstrated science of each drug, a year from today will see blarcamesine in elevated illumination; Aduhelm as a tragic case study in FDA drug approval malfeasance and adherence to a failed Alzheimer's treatment protocol, forcing the body by extraneous, toxic chemical agents to get rid of various protein wastes.

[Investor2014]

Indeed just more Anavex egocentric nonsense.

The world of pharma just doesn’t revolve around a fear of Anavex curing every CNS disease.

How about just waiting and then waiting a bit more see if the AVATAR readout is any good. Geez!

[BIOChecker4]

A company like Samsung would be looking to buy revenue and earnings growth and would be buying at a significant premium. The idea that Samsung would be looking to buy a distressed asset that (in your mind at least) is akin to a disaster is simply illogical and not how these things work.

[tredenwater2]

It's not about us. Biogen couldn't even imagine Anavex as a possible solution or future deadly competitor. They were going down with their amyloid ship and are now looking for a tow.

Pride comes before the fall and greed is sure to not be far behind, now look at them. Its absolutely amazing how inside the box thinking some company’s are after decades of chasing the wrong solution. In other words its hard to “ think differently and without fear.”